 | • レポートコード：MRC2-11QY01905 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、181ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は腎臓がん治療薬のグローバル市場について調査・分析したレポートです。種類別（血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2））市場規模、用途別（腎細胞癌（RCC）、移行上皮癌（TCC））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別腎臓がん治療薬の競争状況、市場シェア ・世界の腎臓がん治療薬市場：種類別市場規模 2015年-2020年（血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2）） ・世界の腎臓がん治療薬市場：種類別市場規模予測 2021年-2026年（血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2）） ・世界の腎臓がん治療薬市場：用途別市場規模 2015年-2020年（腎細胞癌（RCC）、移行上皮癌（TCC）） ・世界の腎臓がん治療薬市場：用途別市場規模予測 2021年-2026年（腎細胞癌（RCC）、移行上皮癌（TCC）） ・北米の腎臓がん治療薬市場分析：米国、カナダ ・ヨーロッパの腎臓がん治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの腎臓がん治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の腎臓がん治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの腎臓がん治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bayer、Roche、GlaxoSmithKline、Novartis、Pfizer、Abbott Laboratories、Active Biotech、Amgen、Argos Therapeutics、ArQule、AVEO Pharmaceuticals、Bionomics、Bristol-Myers Squibb、Cerulean Pharma、Exelixis、Genentech、immatics biotechnologies、Immunicum、Ono Pharmaceutical、Onyx Therapeutics、Oxford BioMedica、Prometheus Laboratories、Seattle Genetics、Taiwan Liposome、Tracon Pharmaceuticals、Wilex ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
Market Analysis and Insights: Global Kidney Cancer Drugs Market
The global Kidney Cancer Drugs market size is projected to reach US$ 4092.9 million by 2026, from US$ 3910.4 million in 2020, at a CAGR of 4.3%% during 2021-2026.
Global Kidney Cancer Drugs Scope and Market Size
Kidney Cancer Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Kidney Cancer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Kidney Cancer Drugs market is segmented into
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Segment by Application, the Kidney Cancer Drugs market is segmented into
Renal cell carcinoma (RCC)
Transitional cell carcinoma (TCC)
Regional and Country-level Analysis
The Kidney Cancer Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Kidney Cancer Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Kidney Cancer Drugs Market Share Analysis
Kidney Cancer Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Kidney Cancer Drugs business, the date to enter into the Kidney Cancer Drugs market, Kidney Cancer Drugs product introduction, recent developments, etc.
The major vendors covered:
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
1 Study Coverage
1.1 Kidney Cancer Drugs Product Introduction
1.2 Market Segments
1.3 Key Kidney Cancer Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Kidney Cancer Drugs Market Size Growth Rate by Type
1.4.2 Angiogenesis Inhibitors
1.4.3 mTOR Inhibitors
1.4.4 Monoclonal Antibodies
1.4.5 Cytokine Immunotherapy (IL-2)
1.5 Market by Application
1.5.1 Global Kidney Cancer Drugs Market Size Growth Rate by Application
1.5.2 Renal cell carcinoma (RCC)
1.5.3 Transitional cell carcinoma (TCC)
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Kidney Cancer Drugs Market Size, Estimates and Forecasts
2.1.1 Global Kidney Cancer Drugs Revenue 2015-2026
2.1.2 Global Kidney Cancer Drugs Sales 2015-2026
2.2 Global Kidney Cancer Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Kidney Cancer Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Kidney Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Kidney Cancer Drugs Competitor Landscape by Players
3.1 Kidney Cancer Drugs Sales by Manufacturers
3.1.1 Kidney Cancer Drugs Sales by Manufacturers (2015-2020)
3.1.2 Kidney Cancer Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Kidney Cancer Drugs Revenue by Manufacturers
3.2.1 Kidney Cancer Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Kidney Cancer Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Kidney Cancer Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Kidney Cancer Drugs Revenue in 2019
3.2.5 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Kidney Cancer Drugs Price by Manufacturers
3.4 Kidney Cancer Drugs Manufacturing Base Distribution, Product Types
3.4.1 Kidney Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Kidney Cancer Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Kidney Cancer Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Kidney Cancer Drugs Market Size by Type (2015-2020)
4.1.1 Global Kidney Cancer Drugs Sales by Type (2015-2020)
4.1.2 Global Kidney Cancer Drugs Revenue by Type (2015-2020)
4.1.3 Kidney Cancer Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Kidney Cancer Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Kidney Cancer Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Kidney Cancer Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Kidney Cancer Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Kidney Cancer Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Kidney Cancer Drugs Market Size by Application (2015-2020)
5.1.1 Global Kidney Cancer Drugs Sales by Application (2015-2020)
5.1.2 Global Kidney Cancer Drugs Revenue by Application (2015-2020)
5.1.3 Kidney Cancer Drugs Price by Application (2015-2020)
5.2 Kidney Cancer Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Kidney Cancer Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Kidney Cancer Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Kidney Cancer Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Kidney Cancer Drugs by Country
6.1.1 North America Kidney Cancer Drugs Sales by Country
6.1.2 North America Kidney Cancer Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Kidney Cancer Drugs Market Facts & Figures by Type
6.3 North America Kidney Cancer Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Kidney Cancer Drugs by Country
7.1.1 Europe Kidney Cancer Drugs Sales by Country
7.1.2 Europe Kidney Cancer Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Kidney Cancer Drugs Market Facts & Figures by Type
7.3 Europe Kidney Cancer Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Kidney Cancer Drugs by Region
8.1.1 Asia Pacific Kidney Cancer Drugs Sales by Region
8.1.2 Asia Pacific Kidney Cancer Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Type
8.3 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Kidney Cancer Drugs by Country
9.1.1 Latin America Kidney Cancer Drugs Sales by Country
9.1.2 Latin America Kidney Cancer Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Kidney Cancer Drugs Market Facts & Figures by Type
9.3 Central & South America Kidney Cancer Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Kidney Cancer Drugs by Country
10.1.1 Middle East and Africa Kidney Cancer Drugs Sales by Country
10.1.2 Middle East and Africa Kidney Cancer Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Description and Business Overview
11.1.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bayer Kidney Cancer Drugs Products Offered
11.1.5 Bayer Related Developments
11.2 Roche
11.2.1 Roche Corporation Information
11.2.2 Roche Description and Business Overview
11.2.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Roche Kidney Cancer Drugs Products Offered
11.2.5 Roche Related Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Description and Business Overview
11.3.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Kidney Cancer Drugs Products Offered
11.3.5 GlaxoSmithKline Related Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Description and Business Overview
11.4.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novartis Kidney Cancer Drugs Products Offered
11.4.5 Novartis Related Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Description and Business Overview
11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Kidney Cancer Drugs Products Offered
11.5.5 Pfizer Related Developments
11.6 Abbott Laboratories
11.6.1 Abbott Laboratories Corporation Information
11.6.2 Abbott Laboratories Description and Business Overview
11.6.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Abbott Laboratories Kidney Cancer Drugs Products Offered
11.6.5 Abbott Laboratories Related Developments
11.7 Active Biotech
11.7.1 Active Biotech Corporation Information
11.7.2 Active Biotech Description and Business Overview
11.7.3 Active Biotech Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Active Biotech Kidney Cancer Drugs Products Offered
11.7.5 Active Biotech Related Developments
11.8 Amgen
11.8.1 Amgen Corporation Information
11.8.2 Amgen Description and Business Overview
11.8.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Amgen Kidney Cancer Drugs Products Offered
11.8.5 Amgen Related Developments
11.9 Argos Therapeutics
11.9.1 Argos Therapeutics Corporation Information
11.9.2 Argos Therapeutics Description and Business Overview
11.9.3 Argos Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Argos Therapeutics Kidney Cancer Drugs Products Offered
11.9.5 Argos Therapeutics Related Developments
11.10 ArQule
11.10.1 ArQule Corporation Information
11.10.2 ArQule Description and Business Overview
11.10.3 ArQule Sales, Revenue and Gross Margin (2015-2020)
11.10.4 ArQule Kidney Cancer Drugs Products Offered
11.10.5 ArQule Related Developments
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Description and Business Overview
11.1.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bayer Kidney Cancer Drugs Products Offered
11.1.5 Bayer Related Developments
11.12 Bionomics
11.12.1 Bionomics Corporation Information
11.12.2 Bionomics Description and Business Overview
11.12.3 Bionomics Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Bionomics Products Offered
11.12.5 Bionomics Related Developments
11.13 Bristol-Myers Squibb
11.13.1 Bristol-Myers Squibb Corporation Information
11.13.2 Bristol-Myers Squibb Description and Business Overview
11.13.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Bristol-Myers Squibb Products Offered
11.13.5 Bristol-Myers Squibb Related Developments
11.14 Cerulean Pharma
11.14.1 Cerulean Pharma Corporation Information
11.14.2 Cerulean Pharma Description and Business Overview
11.14.3 Cerulean Pharma Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Cerulean Pharma Products Offered
11.14.5 Cerulean Pharma Related Developments
11.15 Exelixis
11.15.1 Exelixis Corporation Information
11.15.2 Exelixis Description and Business Overview
11.15.3 Exelixis Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Exelixis Products Offered
11.15.5 Exelixis Related Developments
11.16 Genentech
11.16.1 Genentech Corporation Information
11.16.2 Genentech Description and Business Overview
11.16.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Genentech Products Offered
11.16.5 Genentech Related Developments
11.17 immatics biotechnologies
11.17.1 immatics biotechnologies Corporation Information
11.17.2 immatics biotechnologies Description and Business Overview
11.17.3 immatics biotechnologies Sales, Revenue and Gross Margin (2015-2020)
11.17.4 immatics biotechnologies Products Offered
11.17.5 immatics biotechnologies Related Developments
11.18 Immunicum
11.18.1 Immunicum Corporation Information
11.18.2 Immunicum Description and Business Overview
11.18.3 Immunicum Sales, Revenue and Gross Margin (2015-2020)
11.18.4 Immunicum Products Offered
11.18.5 Immunicum Related Developments
11.19 Ono Pharmaceutical
11.19.1 Ono Pharmaceutical Corporation Information
11.19.2 Ono Pharmaceutical Description and Business Overview
11.19.3 Ono Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.19.4 Ono Pharmaceutical Products Offered
11.19.5 Ono Pharmaceutical Related Developments
11.20 Onyx Therapeutics
11.20.1 Onyx Therapeutics Corporation Information
11.20.2 Onyx Therapeutics Description and Business Overview
11.20.3 Onyx Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.20.4 Onyx Therapeutics Products Offered
11.20.5 Onyx Therapeutics Related Developments
11.21 Oxford BioMedica
11.21.1 Oxford BioMedica Corporation Information
11.21.2 Oxford BioMedica Description and Business Overview
11.21.3 Oxford BioMedica Sales, Revenue and Gross Margin (2015-2020)
11.21.4 Oxford BioMedica Products Offered
11.21.5 Oxford BioMedica Related Developments
11.22 Prometheus Laboratories
11.22.1 Prometheus Laboratories Corporation Information
11.22.2 Prometheus Laboratories Description and Business Overview
11.22.3 Prometheus Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.22.4 Prometheus Laboratories Products Offered
11.22.5 Prometheus Laboratories Related Developments
11.23 Seattle Genetics
11.23.1 Seattle Genetics Corporation Information
11.23.2 Seattle Genetics Description and Business Overview
11.23.3 Seattle Genetics Sales, Revenue and Gross Margin (2015-2020)
11.23.4 Seattle Genetics Products Offered
11.23.5 Seattle Genetics Related Developments
11.24 Taiwan Liposome
11.24.1 Taiwan Liposome Corporation Information
11.24.2 Taiwan Liposome Description and Business Overview
11.24.3 Taiwan Liposome Sales, Revenue and Gross Margin (2015-2020)
11.24.4 Taiwan Liposome Products Offered
11.24.5 Taiwan Liposome Related Developments
11.25 Tracon Pharmaceuticals
11.25.1 Tracon Pharmaceuticals Corporation Information
11.25.2 Tracon Pharmaceuticals Description and Business Overview
11.25.3 Tracon Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.25.4 Tracon Pharmaceuticals Products Offered
11.25.5 Tracon Pharmaceuticals Related Developments
11.26 Wilex
11.26.1 Wilex Corporation Information
11.26.2 Wilex Description and Business Overview
11.26.3 Wilex Sales, Revenue and Gross Margin (2015-2020)
11.26.4 Wilex Products Offered
11.26.5 Wilex Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Kidney Cancer Drugs Market Estimates and Projections by Region
12.1.1 Global Kidney Cancer Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Kidney Cancer Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Kidney Cancer Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Kidney Cancer Drugs Sales Forecast (2021-2026)
12.2.2 North America: Kidney Cancer Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Kidney Cancer Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Kidney Cancer Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Kidney Cancer Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Kidney Cancer Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Kidney Cancer Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Kidney Cancer Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Kidney Cancer Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Kidney Cancer Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Kidney Cancer Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Kidney Cancer Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Kidney Cancer Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Kidney Cancer Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Kidney Cancer Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Kidney Cancer Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Kidney Cancer Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Kidney Cancer Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Kidney Cancer Drugs Market Segments
Table 2. Ranking of Global Top Kidney Cancer Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Kidney Cancer Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Angiogenesis Inhibitors
Table 5. Major Manufacturers of mTOR Inhibitors
Table 6. Major Manufacturers of Monoclonal Antibodies
Table 7. Major Manufacturers of Cytokine Immunotherapy (IL-2)
Table 8. Global Kidney Cancer Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Kidney Cancer Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Kidney Cancer Drugs Sales by Regions 2015-2020 (K Units)
Table 11. Global Kidney Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Kidney Cancer Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Kidney Cancer Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global Kidney Cancer Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Kidney Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Kidney Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Drugs as of 2019)
Table 17. Kidney Cancer Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Kidney Cancer Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Kidney Cancer Drugs Price (2015-2020) (USD/Unit)
Table 20. Kidney Cancer Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Kidney Cancer Drugs Product Type
Table 22. Date of International Manufacturers Enter into Kidney Cancer Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 25. Global Kidney Cancer Drugs Sales Share by Type (2015-2020)
Table 26. Global Kidney Cancer Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Kidney Cancer Drugs Revenue Share by Type (2015-2020)
Table 28. Kidney Cancer Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 30. Global Kidney Cancer Drugs Sales Share by Application (2015-2020)
Table 31. North America Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 32. North America Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 36. North America Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 38. North America Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 40. Europe Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 44. Europe Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 46. Europe Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Kidney Cancer Drugs Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific Kidney Cancer Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Kidney Cancer Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Kidney Cancer Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 56. Latin America Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 60. Latin America Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 62. Latin America Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
Table 71. Bayer Corporation Information
Table 72. Bayer Description and Major Businesses
Table 73. Bayer Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Bayer Product
Table 75. Bayer Recent Development
Table 76. Roche Corporation Information
Table 77. Roche Description and Major Businesses
Table 78. Roche Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Roche Product
Table 80. Roche Recent Development
Table 81. GlaxoSmithKline Corporation Information
Table 82. GlaxoSmithKline Description and Major Businesses
Table 83. GlaxoSmithKline Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. GlaxoSmithKline Product
Table 85. GlaxoSmithKline Recent Development
Table 86. Novartis Corporation Information
Table 87. Novartis Description and Major Businesses
Table 88. Novartis Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Novartis Product
Table 90. Novartis Recent Development
Table 91. Pfizer Corporation Information
Table 92. Pfizer Description and Major Businesses
Table 93. Pfizer Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Pfizer Product
Table 95. Pfizer Recent Development
Table 96. Abbott Laboratories Corporation Information
Table 97. Abbott Laboratories Description and Major Businesses
Table 98. Abbott Laboratories Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. Abbott Laboratories Product
Table 100. Abbott Laboratories Recent Development
Table 101. Active Biotech Corporation Information
Table 102. Active Biotech Description and Major Businesses
Table 103. Active Biotech Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Active Biotech Product
Table 105. Active Biotech Recent Development
Table 106. Amgen Corporation Information
Table 107. Amgen Description and Major Businesses
Table 108. Amgen Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Amgen Product
Table 110. Amgen Recent Development
Table 111. Argos Therapeutics Corporation Information
Table 112. Argos Therapeutics Description and Major Businesses
Table 113. Argos Therapeutics Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Argos Therapeutics Product
Table 115. Argos Therapeutics Recent Development
Table 116. ArQule Corporation Information
Table 117. ArQule Description and Major Businesses
Table 118. ArQule Kidney Cancer Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. ArQule Product
Table 120. ArQule Recent Development
Table 121. AVEO Pharmaceuticals Corporation Information
Table 122. AVEO Pharmaceuticals Description and Major Businesses
Table 123. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. AVEO Pharmaceuticals Product
Table 125. AVEO Pharmaceuticals Recent Development
Table 126. Bionomics Corporation Information
Table 127. Bionomics Description and Major Businesses
Table 128. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. Bionomics Product
Table 130. Bionomics Recent Development
Table 131. Bristol-Myers Squibb Corporation Information
Table 132. Bristol-Myers Squibb Description and Major Businesses
Table 133. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. Bristol-Myers Squibb Product
Table 135. Bristol-Myers Squibb Recent Development
Table 136. Cerulean Pharma Corporation Information
Table 137. Cerulean Pharma Description and Major Businesses
Table 138. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. Cerulean Pharma Product
Table 140. Cerulean Pharma Recent Development
Table 141. Exelixis Corporation Information
Table 142. Exelixis Description and Major Businesses
Table 143. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 144. Exelixis Product
Table 145. Exelixis Recent Development
Table 146. Genentech Corporation Information
Table 147. Genentech Description and Major Businesses
Table 148. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 149. Genentech Product
Table 150. Genentech Recent Development
Table 151. immatics biotechnologies Corporation Information
Table 152. immatics biotechnologies Description and Major Businesses
Table 153. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 154. immatics biotechnologies Product
Table 155. immatics biotechnologies Recent Development
Table 156. Immunicum Corporation Information
Table 157. Immunicum Description and Major Businesses
Table 158. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 159. Immunicum Product
Table 160. Immunicum Recent Development
Table 161. Ono Pharmaceutical Corporation Information
Table 162. Ono Pharmaceutical Description and Major Businesses
Table 163. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 164. Ono Pharmaceutical Product
Table 165. Ono Pharmaceutical Recent Development
Table 166. Onyx Therapeutics Corporation Information
Table 167. Onyx Therapeutics Description and Major Businesses
Table 168. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 169. Onyx Therapeutics Product
Table 170. Onyx Therapeutics Recent Development
Table 171. Oxford BioMedica Corporation Information
Table 172. Oxford BioMedica Description and Major Businesses
Table 173. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 174. Oxford BioMedica Product
Table 175. Oxford BioMedica Recent Development
Table 176. Prometheus Laboratories Corporation Information
Table 177. Prometheus Laboratories Description and Major Businesses
Table 178. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 179. Prometheus Laboratories Product
Table 180. Prometheus Laboratories Recent Development
Table 181. Seattle Genetics Corporation Information
Table 182. Seattle Genetics Description and Major Businesses
Table 183. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 184. Seattle Genetics Product
Table 185. Seattle Genetics Recent Development
Table 186. Taiwan Liposome Corporation Information
Table 187. Taiwan Liposome Description and Major Businesses
Table 188. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 189. Taiwan Liposome Product
Table 190. Taiwan Liposome Recent Development
Table 191. Tracon Pharmaceuticals Corporation Information
Table 192. Tracon Pharmaceuticals Description and Major Businesses
Table 193. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 194. Tracon Pharmaceuticals Product
Table 195. Tracon Pharmaceuticals Recent Development
Table 196. Wilex Corporation Information
Table 197. Wilex Description and Major Businesses
Table 198. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 199. Wilex Product
Table 200. Wilex Recent Development
Table 201. Global Kidney Cancer Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 202. Global Kidney Cancer Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 203. Global Kidney Cancer Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 204. Global Kidney Cancer Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 205. North America: Kidney Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 206. North America: Kidney Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 207. Europe: Kidney Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 208. Europe: Kidney Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 209. Asia Pacific: Kidney Cancer Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 210. Asia Pacific: Kidney Cancer Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 211. Latin America: Kidney Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 212. Latin America: Kidney Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 213. Middle East and Africa: Kidney Cancer Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 214. Middle East and Africa: Kidney Cancer Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 215. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 216. Key Challenges
Table 217. Market Risks
Table 218. Main Points Interviewed from Key Kidney Cancer Drugs Players
Table 219. Kidney Cancer Drugs Customers List
Table 220. Kidney Cancer Drugs Distributors List
Table 221. Research Programs/Design for This Report
Table 222. Key Data Information from Secondary Sources
Table 223. Key Data Information from Primary Sources
List of Figures
Figure 1. Kidney Cancer Drugs Product Picture
Figure 2. Global Kidney Cancer Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Angiogenesis Inhibitors Product Picture
Figure 4. mTOR Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Cytokine Immunotherapy (IL-2) Product Picture
Figure 7. Global Kidney Cancer Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Renal cell carcinoma (RCC)
Figure 9. Transitional cell carcinoma (TCC)
Figure 10. Kidney Cancer Drugs Report Years Considered
Figure 11. Global Kidney Cancer Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Kidney Cancer Drugs Sales 2015-2026 (K Units)
Figure 13. Global Kidney Cancer Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Kidney Cancer Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Kidney Cancer Drugs Sales Market Share by Region in 2019
Figure 16. Global Kidney Cancer Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Kidney Cancer Drugs Revenue Market Share by Region in 2019
Figure 18. Global Kidney Cancer Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Kidney Cancer Drugs Revenue in 2019
Figure 20. Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Kidney Cancer Drugs Sales Market Share by Type in 2019
Figure 23. Global Kidney Cancer Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Kidney Cancer Drugs Revenue Market Share by Type in 2019
Figure 25. Global Kidney Cancer Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Kidney Cancer Drugs Sales Market Share by Application in 2019
Figure 28. Global Kidney Cancer Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Kidney Cancer Drugs Revenue Market Share by Application in 2019
Figure 30. North America Kidney Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 31. North America Kidney Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Kidney Cancer Drugs Sales Market Share by Country in 2019
Figure 33. North America Kidney Cancer Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 35. U.S. Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 37. Canada Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Kidney Cancer Drugs Market Share by Type in 2019
Figure 39. North America Kidney Cancer Drugs Market Share by Application in 2019
Figure 40. Europe Kidney Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 41. Europe Kidney Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Kidney Cancer Drugs Sales Market Share by Country in 2019
Figure 43. Europe Kidney Cancer Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 45. Germany Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 47. France Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. U.K. Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. Italy Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. Russia Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Kidney Cancer Drugs Market Share by Type in 2019
Figure 55. Europe Kidney Cancer Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Kidney Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 57. Asia Pacific Kidney Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Kidney Cancer Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Kidney Cancer Drugs Revenue Market Share by Region in 2019
Figure 60. China Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 61. China Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 63. Japan Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. South Korea Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. India Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. Australia Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. Taiwan Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Indonesia Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Thailand Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Malaysia Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Philippines Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Vietnam Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Kidney Cancer Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Kidney Cancer Drugs Market Share by Application in 2019
Figure 84. Latin America Kidney Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 85. Latin America Kidney Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Kidney Cancer Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Kidney Cancer Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 89. Mexico Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 91. Brazil Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 93. Argentina Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Kidney Cancer Drugs Market Share by Type in 2019
Figure 95. Latin America Kidney Cancer Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Kidney Cancer Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 97. Middle East and Africa Kidney Cancer Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 101. Turkey Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 103. Saudi Arabia Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Kidney Cancer Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 105. U.A.E Kidney Cancer Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Kidney Cancer Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Kidney Cancer Drugs Market Share by Application in 2019
Figure 108. North America Kidney Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 109. North America Kidney Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Kidney Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 111. Europe Kidney Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Kidney Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 113. Asia Pacific Kidney Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Kidney Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 115. Latin America Kidney Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Kidney Cancer Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 117. Middle East and Africa Kidney Cancer Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
腎臓/腎がん治療薬の世界市場（～2026年） Kidney/Renal Cancer Drugs are used to cure kidney cancers. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. Rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors bo…- 腎臓がんの世界市場（～2026年） Kidney cancer is a type of cancer that starts in the cells in the kidney. The growth of the market is attributed to increasing incidence of kidney cancers and increasing ill lifestyle changes which gets worsen with addiction of tobacco and alcohol. Furthermore, overexposure to radiation during treat…
- 頭頸部がん治療薬/治療の世界市場（～2026年） Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands. Current trends indicate that rising geriatric population worldwide, growing cases of target diseases, and availability of improved healthcare services due to government and private…
- 免疫療法薬の世界市場（～2026年） Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. North America is expected to account for largest share in the …
- 腎細胞がん治療薬の世界市場（～2026年） Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is …